EAACI has developed a clinical practice guideline providing evidence-based recommendations for the use of house dust mite (HDM) AIT as add-on treatment for HDM-driven allergic asthma.

This Guideline has been prepared by the Taskforce on AIT for Allergic Asthma and is part of the EAACI Guidelines on Allergen Immunotherapy. Recommendations were formulated by a multi-disciplinary working group aiming to provide indications and contraindications to HDM AIT as add-on treatment for HDM-driven allergic asthma and to identify gaps in knowledge and/or implementation, unmet needs and future perspectives.

The new EAACI Guidelines on Allergen Immunotherapy: house dust mite-driven allergic asthma are now out!
Last updated 29 August 2019
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Send feedback